Company profile: GenomeDx
1.1 - Company Overview
Company description
- Provider of genomic-based laboratory tests for personalized medicine in cancer care, including the Decipher Prostate Cancer Classifier for independent assessment of tumor aggressiveness, the Decipher GRID genomic expression database in urologic cancer, and genomic testing and a development pipeline focused on creating genomic tests for urologic cancers to aid personalized treatment decisions.
Products and services
- Decipher GRID: A population-scale genomic expression database in urologic cancer, housing data from thousands of patients to aid research and inform treatment strategies
- Decipher Prostate Cancer Classifier: A genomic-based classifier that delivers an independent assessment of prostate tumor aggressiveness, supplying information distinct from Gleason score or PSA to inform personalized care
- Genomic Testing in Urologic Cancer: Laboratory-grade tests that assess gene activity to deliver information about tumor behavior, aiding personalized treatment decisions in urologic cancer care
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to GenomeDx
Chinook Therapeutics
HQ: Canada
Website
- Description: Provider of precision medicines for kidney diseases, leveraging novel translational platforms and patient stratification tools. Pipeline includes Atrasentan, a selective ETA receptor antagonist in phase 3 for IgA nephropathy and phase 2 for other proteinuric glomerular diseases; Zigakibart (BION-1301), an anti-APRIL monoclonal antibody in phase 3 and phase 1/2 for IgA nephropathy; and CHK-336, an oral LDHA inhibitor in phase 1 for primary and idiopathic hyperoxaluria.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chinook Therapeutics company profile →
EMulate Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage therapeutic devices using proprietary ultra-low radio frequency energy (ulRFE) to elicit therapeutic biological effects. Programs include clinical testing in brain cancer and preclinical work in pain and mental health, advanced by subsidiaries: Cellsana (oncology; Phase III prep for glioblastoma/diffuse midline glioma), Mensana (mental health; Phase I prep), and Indolor (pain; Phase I prep).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EMulate Therapeutics company profile →
IO Biotech
HQ: Denmark
Website
- Description: Provider of immune-modulating cancer therapies built on its T-win technology, activating T cells against tumor and immune-suppressive cells. Offers IO102-IO103 T-win vaccines targeting IDO and PD-L1, used with anti-PD-1 therapy for metastatic melanoma, and runs Phase 2/3 trials with pembrolizumab in melanoma, lung, head and neck, and bladder cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IO Biotech company profile →
PACT Pharma
HQ: United States
Website
- Description: Provider of personalized adoptive T cell therapies designed for the eradication of solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PACT Pharma company profile →
Iambic Therapeutics
HQ: United States
Website
- Description: Provider of an AI-driven drug-discovery platform to optimize drug profiles and identify novel mechanisms of action, featuring NeuralPlexer (3D physics-based generative diffusion for protein-ligand structures), OrbNet (protein-ligand binding energetics), PropANE (multi-parameter lead selection), and Magnet (generative molecular design), plus a first-in-class CDK2/4 candidate for cyclin D- and E-driven cancers with reduced off-target toxicities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Iambic Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for GenomeDx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to GenomeDx
2.2 - Growth funds investing in similar companies to GenomeDx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for GenomeDx
4.2 - Public trading comparable groups for GenomeDx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →